Roche Diagnostics has made its Endotrophin research prototype assay available on cobas e801 analyzers at Nordic Bioscience's CLIA laboratory. This marks the second biomarker collaboration between the two companies, following the launch of Elecsys PRO-C3, and aims to advance research into fibro-inflammatory risks associated with cardio-renal-metabolic syndromes.
Roche Diagnostics is making its Endotrophin research prototype assay available on its cobas e801 analyzers at Nordic Bioscience's CLIA lab, the second biomarker from the collaboration after Elecsys PRO-C3. This is an early-stage research tool with no revenue, volume or order figures, so the financial effect on Roche shares is negligible; the press release is corporate self-description without a hard quantified fact.